119
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes

&
Pages 297-304 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Edward P. Armstrong, Grant H. Skrepnek, Medha Sasane, Susan M. Snodgrass & Samir K. Ballas. (2013) Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. Journal of Medical Economics 16:1, pages 10-18.
Read now

Articles from other publishers (2)

Kathryn Doig. 2020. Rodak's Hematology. Rodak's Hematology 264 281 .
Richard K. Watt, Robert J. Hilton & D. Matthew Graff. (2010) Oxido-reduction is not the only mechanism allowing ions to traverse the ferritin protein shell. Biochimica et Biophysica Acta (BBA) - General Subjects 1800:8, pages 745-759.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.